Cellectar Biosciences (Warrant)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch CLRBZ and buy or sell other stocks, options, and ETFs commission-free!

About CLRBZ

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. 

CEO
James V. Caruso
CEOJames V. Caruso
Employees
Employees
Headquarters
Florham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded
1996
Founded1996
Employees
Employees

CLRBZ Key Statistics

Market cap
Market cap
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
52 Week high
52 Week low
52 Week low

CLRBZ News

Yahoo Finance 14h
Cellectar Biosciences, Inc. Q4 2023 Earnings Call Transcript - Yahoo Finance

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024 Cellectar Biosciences, Inc. isn't one of the 30 most popular stocks a...

Cellectar Biosciences, Inc. Q4 2023 Earnings Call Transcript - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.